3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Genitourinary
1
CNS
1
Conditions
Glioma
3
Wilms Tumor
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioblastoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Interventions
Filgrastim
11
Temozolomide
9
Melphalan
9
Cyclophosphamide
9
Radiotherapy
7
Busulfan
7
Magnetic Resonance Spectroscopy
6
Rituximab
5
Psychiatric Rehabilitation
5
Methotrexate
5
Etoposide
5
Cytarabine
5
Carboplatin
5
sargramostim
4
fludarabine
4
etoposide phosphate
4
Thiotepa
4
Nivolumab
4
Methylprednisolone
4
Flow Cytometry
4
Alemtuzumab
4
Vincristine
3
Topotecan
3
Specimen Handling
3
Peripheral Blood Stem Cell Transplantation
3
Pemetrexed
3
Granulocyte Colony-Stimulating Factor
3
Early Intervention, Educational
3
Drug Therapy
3
Dexamethasone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
CLR1404
×
CNS
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled